Management of Tricuspid Regurgitation in Patients with Rheumatic Mitral Disease
DOI:
https://doi.org/10.48729/pjctvs.604Abstract
Background: Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality in low and middle-income countries, with tricuspid regurgitation (TR) frequently complicating rheumatic mitral pathology. While mild TR often stabilizes after mitral correction, management of moderate and severe TR in this context remains controversial due to limited evidence and applicability of guidelines largely derived from degenerative etiologies. This review synthesizes current data on diagnostic strategies, surgical decision-making, and outcomes in rheumatic TR.
Methods: A comprehensive literature search was performed across PubMed, Google Scholar, and OMNI databases (2010-2024) using the keywords "rheumatic mitral disease," "tricuspid regurgitation," and "management." Eligible studies included clinical trials, case series, reviews, and meta-analyses focusing on TR associated with rheumatic mitral disease. Data was extracted and critically appraised for study design, population, and outcome relevance.
Results: Evidence for managing TR in rheumatic mitral disease primarily stems from retrospective cohorts and small prospective studies, with few randomized trials. Predictors of TR progression include annular dilation (>21 mm/m²), right ventricular dysfunction, pulmonary hypertension, and atrial fibrillation. Mild TR generally regresses following mitral surgery and is managed conservatively. For moderate TR, concomitant repair may prevent late progression and improve hemodynamics, though risks of postoperative arrhythmia and pacemaker implantation persist. Severe TR warrants surgical correction, preferably rigid ring annuloplasty, while valve replacement is reserved for advanced calcific disease. Emerging transcatheter therapies show promise for high-risk patients but lack robust rheumatic-specific data.
Conclusion: Optimal management of TR in rheumatic mitral disease requires individualized, Heart Team-based decision-making due to limited high-quality evidence. Future research should prioritize multicenter trials comparing repair, replacement, and transcatheter approaches, integrating advanced imaging for risk stratification and addressing access disparities in resource-limited settings.
Downloads
References
Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. New England Journal of Medicine. 2017 Aug 24;377(8):713-22.
Salinas A, Gonzalez G, Manuel Ramos J. Rheumatic fever and rheumatic heart disease: collaboration patterns and research core topics. J Heart Valve Dis. 2016;25(5):619-627.
Remenyi B. Rheumatic heart disease of the mitral valve: is there such thing as an ideal operation? Heart Lung Circ. 2018;27(7):779-781.
Arafat AA, Alfonso J, Hassan E, et al. The influence of mitral valve pathology on the concomitant tricuspid valve repair. J Card Surg. 2022;37(4):739-746.
Dreyfus GD, Martin RP, Chan KM, et al. Functional tricuspid regurgitation: a need to revise our understanding. J Am Coll Cardiol. 2015;65(21):2331-2336.
Caldas MMC, Esteves WAM, Nascimento BR, et al. Clinical outcomes and progression rate of tricuspid regurgitation in patients with rheumatic mitral valve disease. Open Heart. 2023;10(2):e002295.
Otto CM. Valvular Heart Disease: A Companion to Braunwald's Heart Disease. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014. p. 123-145. Available at: https://www.elsevier.com/books/valvular-heart-disease/otto/978-0-323-54633-1.
Taramasso M, Gavazzoni M, Pozzoli A, et al. Tricuspid regurgitation: predicting the need for intervention, procedural success, and recurrence of disease. Expert Rev Cardiovasc Ther. 2019;17(11):777-795.
Kim WK, Kim SE, Yoo JS, et al. Impact of valve repair on mild tricuspid insufficiency in rheumatic mitral surgery. J Thorac Cardiovasc Surg. 2023;165(4):1374-1383. e7.
Awad AK, Sayed A, Elbadawy MA, et al. Concomitant tricuspid valve repair for mild-moderate tricuspid regurgitation patients undergoing mitral valve surgery? A meta-analysis and meta-regression. J Cardiovasc Surg (Torino). 2023;64(6):657-667.
Muraru D, Guta AC, Ochoa-Jimenez RC, et al. Functional regurgitation of atrioventricular valves and atrial remodelling: an underestimated association in patients with atrial fibrillation? J Clin Med. 2021;10(5):1103.
Ton-Nu TT, Levine RA, Handschumacher MD, et al. Geometric determinants of functional tricuspid regurgitation: insights from 3-dimensional echocardiography. Circulation. 2006;114(2):143-149.
Mathur A, Sharma N, Goyal P, et al. Surgical algorithm for rheumatic tricuspid disease. Ann Thorac Surg. 2019;108(2):e129-e132.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. Circulation. 2017;135(25):e1159-e1195.
Fawzy HF, Morsy AA, Serag AR, et al. Should moderate functional tricuspid regurgitation be repaired during surgery for rheumatic mitral valve disease? Heart Lung Circ. 2020;29(10):1554-1560.
Naqshband MS, Abid AR, Akhtar RP, et al. Functional tricuspid regurgitation in rheumatic heart disease: surgical options. Ann Thorac Cardiovasc Surg. 2010;16(6):417-425.
Pradhan S, Gautam NC, Singh YM, et al. Tricuspid valve repair: De Vega's tricuspid annuloplasty in moderate secondary tricuspid regurgitation. Kathmandu Univ Med J (KUMJ). 2011;9(33):64-68.
Kim DJ, Lee S, Joo HC, et al. Effect of pulmonary hypertension on clinical outcomes in patients with rheumatic mitral stenosis. Ann Thorac Surg. 2020;109(2):496-503.
Colombo T, Russo C, Ciliberto GR, et al. Tricuspid regurgitation secondary to mitral valve disease: tricuspid annulus function as guide to tricuspid valve repair. Cardiovasc Surg. 2011;9(4):369-377.
Jeong DS, Park PW, Mwambu TP, et al. Tricuspid reoperation after left-sided rheumatic valve operations. Ann Thorac Surg. 2013;95(6):2007-2013.
Ariyoshi T, Hashizume K, Taniguchi S, et al. Which type of secondary tricuspid regurgitation accompanying mitral valve disease should be surgically treated? Ann Thorac Cardiovasc Surg. 2013;19(6):428-434.
Zhong Y, Bai W, Wang H, et al. Impact of concomitant tricuspid annuloplasty on right ventricular remodeling in patients with rheumatic mitral valve disease. Cardiovasc Ultrasound. 2021;19(1):16.
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary. Circulation. 2021;143(5):e35-e71.
Marijon E, Mocumbi A, Narayanan K, et al. Contemporary diagnosis and management of rheumatic heart disease: implications for closing the gap: a scientific statement from the American Heart Association. Circulation. 2020;142(20):e337-e357.
Gatti G, Dell'Angela L, Morosin M, et al. Tricuspid annuloplasty for tricuspid regurgitation secondary to left-sided heart valve disease: immediate outcomes and risk factors for late failure. Can J Cardiol. 2016;32(6):760-766.
Ghoreishi M, Dawood M, Hobbs G, et al. Repeat sternotomy: no longer a risk factor in mitral valve surgical procedures. Ann Thorac Surg. 2013;96(4):1358-1365.
Mathur A, Sharma N, Goyal P, et al. Surgical algorithm for rheumatic tricuspid disease. Ann Thorac Surg. 2019;108(2):e129-e132.
Gammie JS, Chu MW, Falk V, et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med. 2022;386(4):327-339.
Bernhardt AM, Meyer A, Conradi L, et al. Repair of rheumatic tricuspid valve disease: predictors of very long-term mortality and reoperation. Ann Thorac Surg. 2010;90(2):503-508.
Yadlapati A, Groh C, Malaisrie SC, et al. Bioprosthetic tricuspid valve stenosis: management in pregnant women. Circ Cardiovasc Interv. 2016;9(10):e004120.
Dougherty S, Khorsandi M, Herbst P. Rheumatic heart disease screening: what are we waiting for? Cardiovasc J Afr. 2017;28(1):20-23.
Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv. 2019;12(2):155-165.
Hahn RT, George I, Kodali SK, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13(20):2482-2493.
Besler C, Orban M, Rommel KP, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2018;11(12):1119-1129.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
